regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Hangman's Chair were in the habit of recording three or four additional tracks at each studio session for their albums, intended for split-album releases. A split from Hangman's Chair and Drawers was released on 28 March 2012. The following album, Hope /// Dope /// Rope, was released in 2012, via Bones Brigade Records. The album "marked a turning point in our history", said Thépegnier, as the band found "stability" with the arrival of Toufouti and Hanvic, as well as "a musical identity". Documentalist Eric Guillaud wrote that Hope /// Dope /// Rope helped the band make a name for themselves "within the metal community". On 1 February 2014, Hangman's Chair performed at the second edition of JP Fest, a festival that brought together six French metal bands to raise funds for the fight against cancer at the Splendid in Lille. All profits were donated to the Ligue contre le cancer (lit. 'League Against Cancer'), the Lille-based research department of the Oscar-Lambret Centre and the association Accompagnement en Soins Palliatifs (ASP Omega) (lit. 'Accompaniment in Palliative Care'). Their split LP with Acid Deathtrip was released through Reflections Records during the summer of 2014. The band's next album, This Is Not Supposed To Be Positive, was released on 15 September 2015 via the Parisian independent record label Music Fear Satan. The album's release was preceded by a music video for "Dripping Low". Lelo Jimmy Batista, writing for Vice France, described the album as "A kind of Black Sabbath lost at Porte de la Chapelle, an Alice in Chains stranded at Stalingrad".
==== Access from China and United States response ==== In October 2021, following the 2021 Facebook leak and controversies about social media ethics, a bipartisan group of United States lawmakers also pressed TikTok, YouTube, and Snapchat on questions of data privacy and moderation for age-appropriate content. Lawmakers also "hammered" TikTok about whether consumer data could be turned over to the Chinese government through ByteDance, its parent company in China. TikTok said it does not give information to China's government and "US user data" is stored within the country with backups in Singapore. In June 2022, BuzzFeed News reported that leaked audio recordings of internal TikTok meetings reveal employees in China had access to overseas data, including a "master admin" who could see "everything". Some of the recordings were made during consultations with Booz Allen Hamilton, a US government contractor. A spokesperson of the contractor said some of the report's information was inaccurate but would neither confirm nor deny whether TikTok was one of its clients. As a consequence, the Senate Intelligence Committee including US lawmakers Mark Warner and Marco Rubio called for the Federal Communications Commission (FCC) to investigate ByteDance and whether TikTok had misled them. Following the reports, TikTok confirmed that employees in China could have access to US data. It also announced that US user traffic would now be routed through Oracle Cloud and that backup copies would be deleted from other servers.
=== Category:EC 1.9 (act on a heme group of donors) === Category:EC 1.9.3 (with oxygen as acceptor) Cytochrome c oxidase EC 1.9.3.1 Category:EC 1.9.6 (with a nitrogenous as acceptor) Category:EC 1.9.99 transferred, now EC 1.9.98.1
That same day, Peru and the OAS signed a joint declaration in favor of democracy and human rights. The OAS leader Luis Almagro said that "We have seen that president Castillo has much determination to fight corruption, especially corruption that may appear in his government. Let his management be as clean as possible. This requires important efforts in investigation. Let there be a permanent monitoring of transparency, of justice, so that there isn't any element of shadow over official members." On 5 December, Cuarto Poder finally released the audio clip. The audio showed the owner of the Breña house offering "scoops and headlines" to a journalist in exchange for the journalist shelving an unfavorable news story. The host of ATV news, Juliana Oxenford, claimed that it is "much more revealing to know the high content of trans fats in Cheese Tris than the audio of Cuarto Poder." Meanwhile, the journalist Juan Carlos Tafur said that the Cuarto Poder audio "qualifies as a journalistic scam." Following the release of the Cuarto Poder clips, the impeachment motion rapidly fell apart as less hardline members of the opposition rescinded their support for the impeachment motion. On 7 December 2021, with 46 in favor, 76 against, and 4 abstentions, Congress refused to admit the impeachment motion. Following the defeat of the impeachment motion, President Castillo said: "I am grateful that the congressional voted to put Peru first before other interests."
Sources: en.wikipedia.org
The parties will proceed to close the transaction in which funds and title are exchanged. When a deal closes, post-closing processes may begin, including notifying tenants of an ownership change, transferring vendor relationships, and handing over relevant information to the asset management team.
The Earth's cold trap is located about 12 km above sea level, well below the height at which water vapor would be permanently split apart into hydrogen and oxygen by solar UV rays, with the former irreversibly being lost to space. Because of the cold trap in the Earth's atmosphere, the Earth is losing water to space at a rate of only about 1 millimeter of ocean every 1 million years. At that rate, it would take trillions of years for all of its water to disappear, a timescale far longer than Earth's remaining life expectancy. A warmer atmosphere can hold more moisture, consistent with the Clausius–Clapeyron relation. Even with localized warming, the modern cold trap remains robust enough to prevent significant water vapor from being lost to space. However, the gradual luminosity increase of the Sun as it ages will weaken the cold trap over the next billion years by driving a warmer troposphere and stratosphere. This will elevate the mixing ratio of water vapor at the tropopause, allowing moisture to bypass the freeze-drying effect and ascend into the upper atmosphere where it will be dissociated by solar UV rays, leaving hydrogen to escape into space. As a result, the Earth is projected to ultimately lose its oceans to space in approximately 1 to 1.3 billion years, well before the Sun expands into a red giant.
The four substrates of this enzyme are 4-sulfobenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen and a proton. Its products are protocatechuic acid (3,4-dihydroxybenzoic acid), NAD+, and sulfurous acid. This enzyme is an oxidoreductase, which uses molecular oxygen as oxidant and incorporates its atoms into the starting material. The systematic name of this enzyme class is 4-sulfobenzoate,NADH:oxygen oxidoreductase (3,4-hydroxylating, sulfite-forming). Other names in common use include 4-sulfobenzoate dioxygenase, and 4-sulfobenzoate 3,4-dioxygenase system. It participates in toluene degradation and is an iron–sulfur protein that uses flavin mononucleotide as a cofactor.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.